Prachi Tiwari

Lucknow, UP, India

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

In silico design and discovery of pan coronavirus small molecule anti-virals targeting 3CLPRO protease.

In silico design and discovery of pan coronavirus small molecule anti-virals targeting 3CLPRO protease.

Journal: Journal of biomolecular structure & dynamics
Published: December 13, 2024

Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus Retreatment in Difficult-to-treat Patients: A Real-life Observational Study from India.

Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus Retreatment in Difficult-to-treat Patients: A Real-life Observational Study from India.

Journal: Journal of clinical and experimental hepatology
Published: August 18, 2023

Durability of ChAdOx1 nCoV-19 (Covishield®) Vaccine Induced Antibody Response in Health Care Workers.

Durability of ChAdOx1 nCoV-19 (Covishield®) Vaccine Induced Antibody Response in Health Care Workers.

Journal: Vaccines
Published: December 09, 2022

Hepatitis C Retreatment With First-Line Direct Acting Antiviral Drugs.

Hepatitis C Retreatment With First-Line Direct Acting Antiviral Drugs.

Journal: Journal of clinical and experimental hepatology
Published: December 04, 2022

Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield®) in Patients with Liver Cirrhosis.

Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield®) in Patients with Liver Cirrhosis.

Journal: Vaccines
Published: September 29, 2022

Antibody response to ChAdOx1 nCoV-19 (Covishield®) vaccine in people on maintenance hemodialysis.

Antibody response to ChAdOx1 nCoV-19 (Covishield®) vaccine in people on maintenance hemodialysis.

Journal: Seminars in dialysis
Published: September 24, 2022

Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients.

Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients.

Journal: Vaccines
Published: August 14, 2022

Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial).

Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial).

Journal: PloS one
Published: August 10, 2022

Liver Stiffness is Reduced to Normal After Successful Renal Transplantation: A Prospective Cohort Study.

Liver Stiffness is Reduced to Normal After Successful Renal Transplantation: A Prospective Cohort Study.

Journal: Journal of clinical and experimental hepatology
Published: April 19, 2022

Rescue use of Pegylated Interferon in Dialysis Patient who Failed to Respond Sofosbuvir.

Rescue use of Pegylated Interferon in Dialysis Patient who Failed to Respond Sofosbuvir.

Journal: Indian journal of nephrology
Published: June 17, 2021

Use of Sofosbuvir/Velpatasvir/Voxilaprevir for Sofosbuvir Nonresponder Genotype 3 HCV Infection in India.

Use of Sofosbuvir/Velpatasvir/Voxilaprevir for Sofosbuvir Nonresponder Genotype 3 HCV Infection in India.

Journal: Journal of clinical and experimental hepatology
Published: May 22, 2021

Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.

Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: March 03, 2020
Showing 1-12 of 12

Last Updated: 09/26/2026